Newsletter · · Ashutosh Agarwal
Lilly's Amylin Combo Hits 17% Weight Loss as the Compounding Fight Escalates - The GLP-1 Complex - Week of September 21, 2026
The GLP-1 Complex for the week of September 21, 2026. Podcast synthesis on Lilly's low-dose tirzepatide and eloralintide combo hitting 17% weight loss in 16 weeks, a court ruling that lets Lilly's compounding case proceed, a telehealth CEO sizing the peptide gray market at $6 to $8 billion, and read-throughs across restaurants, produce, medtech and payers.
The GLP-1 Complex
Week of September 21, 2026: Lilly's Amylin Combo Hits 17% Weight Loss as the Compounding Fight Escalates
The most useful obesity-drug signal this week came from clinicians, telehealth operators, a consumer researcher, and a restaurant editor rather than the big finance podcasts. Taken together they tell you two things at once: Eli Lilly is quietly redrawing what "best-in-class" means, and the messy, half-legal edges of this market are far bigger than the models assume.
TL;DR
- Lilly's next act is combinations, not just bigger doses. A low dose of Zepbound paired with Lilly's experimental amylin drug hit 17% weight loss in 16 weeks, roughly retatrutide-like results without needing retatrutide-like doses.
- The gray market is huge. A telehealth CEO pegged the unregulated peptide market at $6-8 billion, two to three times what analysts assume, and says only about 2% of eligible patients are actually on a GLP-1 today.
- The read-throughs are showing up in the real economy. Bariatric surgery is reportedly down about 30%, the US obesity rate is falling for the first time in decades, and roughly one in ten American homes now has a GLP-1 user.
What's new
Lilly's amylin combination is the number that matters. On On The Pen GLP-1 News (Sep 15), the host walked through data Lilly disclosed on eloralintide, its investigational "amylin" drug (a different appetite hormone that also helps preserve muscle), combined with tirzepatide (the molecule in Zepbound). The combo delivered 17% body weight loss in 16 weeks using just 5 mg of tirzepatide plus 3 mg of eloralintide. Tirzepatide alone at that dose did about 10%. Eloralintide on its own reached roughly 20% at 48 weeks. Why it moves numbers: Lilly is showing it can reach top-tier weight loss at a low, well-tolerated dose, which is the whole ballgame for keeping patients on the drug, and for defending pricing as competition arrives.
And Lilly is repositioning retatrutide from "nuclear option" to "everyday drug." Retatrutide (Lilly's triple-hormone candidate) posted a headline 28.3% at its top 12 mg dose, but with heavy nausea and elevated heart rate. This week the host flagged that a Lilly senior executive, speaking over the weekend, described the low end of the curve, about 4 mg, as "roughly terzepatide-like efficacy with very good tolerability," suited to people just starting treatment. That is a real strategic shift. As the host put it, the flashy top-dose figure is like a dating profile: "great lighting, perfect angle." The dose people can actually tolerate is "who actually shows up for the date."
The compounding war just got a court ruling with teeth. Same podcast: on September 8, Judge Jacqueline Scott Corley allowed Lilly's California unfair-competition claim against Equida Pharmacy (tied to the Lilly v. Mochi Health case) to proceed. Lilly alleges the pharmacy "filed large numbers of identical prescriptions despite compounded medications being presented as individualized treatment." In plain terms, that means mass-producing a drug while calling it custom-made, which compounding rules do not allow. These are still allegations, but discovery could pry open how these telehealth-and-pharmacy setups really work.
A telehealth CEO says the shadow market is enormous. On Hims House (Sep 16), the CEO of OpenLoop (a telehealth infrastructure company) argued the gray market for compounded and imported peptides is "2-3x bigger than analyst estimates, likely $6-8 billion." He also threw cold water on how mature the market is:
"Still about only 2% of total eligible patients for GLP-1s are actively on them. So there's still some really significant upside within this market."
He expects cash-pay prices to keep falling, echoing Hims CEO Andrew Dudum's call for $40-$50 a month by around 2030, and, longer term, sees GLP-1s becoming as routine as statins, guessing "80% of the population above the age of 30" could eventually be on them. That is an operator talking his book, but the direction is the point.
The debate
The bull case (well voiced this week): penetration is a rounding error, and the drugs keep getting better. If only ~2% of eligible patients are actually treated, if cash prices are heading toward $40-$50 a month, and if Lilly can deliver ~17% weight loss at low, tolerable doses, then the addressable market is nowhere near tapped out. The OpenLoop CEO's framing, GLP-1s as a lifelong preventive drug like a statin, is the maximalist version of this. Cheaper pills plus better tolerability plus a still-tiny treated share is a long runway.
The bear case (quieter, but real): tolerability, staying power, and payer fatigue. The most sober voice came from The Bio Report (Sep 16), where Wave Life Sciences Chief Scientific Officer Eric Ingelson made the case that today's drugs have a body-composition problem:
"Traditionally, with an incretin therapy, you would have up to 40% of your weight loss coming from muscle, which... is not a good thing."
He added the staying-power stat that should worry anyone modeling lifetime revenue: "70% of individuals have started an incretin and have stopped within the first year." His pitch is that the next competitive axis is quality of weight loss (losing fat, keeping muscle), which is exactly the gap Lilly's amylin combo is aiming at. The skepticism this week was about how the drugs work, not whether they sell.
Read-throughs
Restaurants and consumer: the user base is shifting, and it's bigger than the headlines feel. On A Deeper Dive (Sep 16), consumer researcher Lisa Miller said the fastest-growing group of new users is now men, specifically executives, partly because men report fewer side effects in trials and stay on the drug. She put current usage around 10-12% and warned operators not to be lulled by a seasonally slow moment: a "wave three" ramp is coming in January. Her most investable detail was on older patients: her July data showed a jump in baby boomers starting, because through a government "bridge program" it now costs "only $50."
Packaged food and produce: a slow reshaping of the plate. On The Produce Moms Podcast (Sep 16), Grimmway Produce Group marketing VP Karen White said "10% of homes have a GLP-1 user in them and it's going to grow," and argued the trend is boosting demand for "functional foods" (high-protein, high-fiber, nutrient-dense options) because people eating less want every calorie to count. That is a tailwind for fresh produce and a headwind narrative for high-calorie snacking (think PEP, MDLZ, HSY) that the confectioners have long disputed.
Medtech and hospitals: the downstream bill is coming due. On DGTL Voices with Ed Marx (Sep 17), digital-health physician Joel Selanikio said the US obesity rate is falling "for the first time in... 30 years," with GLP-1s the only credible explanation, and that bariatric surgery has "decreased in the last few years by 30%." His broader warning is for hospital revenue lines that sit downstream of obesity (stents, diabetic eye care, some cancers, and knee and hip replacements; read: ISRG, SYK, ZBH), which he says are "in the billions." It is one expert's framing, not hard company data, but it is the clearest articulation this week of why GLP-1s are a device-sector problem, not just a pharma story.
The names in play
Payers, via an unlikely example: Cigna. On the Across The Bar Podcast (Sep 17), the hosts flagged that Cigna, an insurer, removed GLP-1 coverage from its own employees' benefits on cost grounds, prompting 450 employees to sign a petition, with personal stories, asking for it back. It is a small anecdote with a big implication: if even a health insurer is balking at the cost for its own staff, employer and pharmacy-benefit pushback on obesity coverage is far from settled, and gross-to-net pressure (the gap between list price and what drugmakers actually collect after rebates) has room to grind higher.